Veterinary good pharmacovigilance practices (VGVP)
VeterinaryRegulatory and procedural guidancePharmacovigilance
On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.
Updated 4 December 2025:
'Veterinary Union Pharmacovigilance Database - Best Practice Guide' section
Veterinary good pharmacovigilance practices (VGVP) are a set of measures to facilitate pharmacovigilance for veterinary medicines in the European Union (EU) / European Economic Area (EEA). They apply to marketing-authorisation holders, the European Medicines Agency (EMA) and medicines regulatory authorities in EU Member States.
They cover veterinary medicines authorised centrally via the Agency as well as medicines authorised at national level.
As of 28 January 2022, the VGVP guideline superseded previous EU guidance on pharmacovigilance for veterinary medicines.
This document has replaced the previous EudraVigilance Veterinary – Best Practice Guide and covers guidance for all registered user organisations and their individual users (EVWEB and Gateway users) that record suspected adverse event reports (AERs) in EudraVigilance Veterinary (EVV), as well as practical advice to facilitate the implementation of the following veterinary good pharmacovigilance practices (VGVP) modules: Collection and recording of suspected adverse events for veterinary medicinal products, Signal Management and Controls and pharmacovigilance Inspections.